Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel

BEIJING, Oct. 6 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company has retained Sichenzia Ross Friedman Ference LLP ("SRFF") as its general corporate legal counsel.

"Sichenzia Ross Friedman Ference has a very successful track record advising and representing clients in the China space, and we are very pleased to benefit from their counsel as we expand our distribution channels and continue to develop our internal drug pipeline," said Dr. Zhongyi Liu, Lotus' Chairman and Chief Executive Officer. "As we grow and capitalize on the enormous pharmaceuticals demand in China, we are confident that our relationship with SRFF will allow us to remain in compliance with all of the requisite U.S. legal and regulatory standards."

Sichenzia Ross Friedman Ference LLP represents a wide client base that includes private and public corporations, partnerships, broker-dealers, bank-affiliated broker-dealers, investment advisors, registered personnel, public and corporate customers and investors, and other entities. The firm also advises institutional investors on transactions involving complex securities law considerations. SRFF represents clients located in the United States and throughout the world.

The firm's areas of expertise include corporate and commercial transactions, securities litigation and arbitration, administrative practice before regulatory agencies, mergers and acquisitions, and broker-dealer regulation. In addition, SRFF provides guidance to Asian companies seeking guidance for corporate finance and merger and acquisition activity and investors seeking business opportunities in China.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

About Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP represents over 150 publicly traded companies, with approximately 50 located in China. SRFF has been ranked # 1 in representing public companies in PIPE transactions, both domestic and international, since 2004. The New York-based firm has completed over 300 such transactions totaling over $2 billion.  In 2009, SRFF was responsible for assisting the largest number of China-based companies graduate from trading on the OTCBB to listing on the NYSE Amex. SRFF provides experienced, professional representation in all matters involving the securities industry, as well as in all general corporate and litigation matters. SRFF's clients range from start-ups to established, listed companies. For more information, visit www.SRFF.com.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

SOURCE Lotus Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED